The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Ketamine for chronic pain: risks and benefits
Open accessAbstract
The anaesthetic ketamine is used to treat various chronic pain syndromes, especially those that have a neuropathic component. Low dose ketamine produces strong analgesia in neuropathic pain states, presumably by inhibition of the N‐methyl‐D‐aspartate receptor although other mechanisms are possibly involved, including enhancement of descending inhibition and anti‐inflammatory effects at central sites. Current data on short term infusions indicate that ketamine produces potent analgesia during administration only, while three studies on the effect of prolonged infusion (4–14 days) show long‐term analgesic effects up to 3 months following infusion. The side effects of ketamine noted in clinical studies include psychedelic symptoms (hallucinations, memory defects, panic attacks), nausea/vomiting, somnolence, cardiovascular stimulation and, in a minority of patients, hepatoxicity. The recreational use of ketamine is increasing and comes with a variety of additional risks ranging from bladder and renal complications to persistent psychotypical behaviour and memory defects. Blind extrapolation of these risks to clinical patients is difficult because of the variable, high and recurrent exposure to the drug in ketamine abusers and the high frequency of abuse of other illicit substances in this population. In clinical settings, ketamine is well tolerated, especially when benzodiazepines are used to tame the psychotropic side effects. Irrespective, close monitoring of patients receiving ketamine is mandatory, particularly aimed at CNS, haemodynamic, renal and hepatic symptoms as well as abuse. Further research is required to assess whether the benefits outweigh the risks and costs. Until definite proof is obtained ketamine administration should be restricted to patients with therapy‐resistant severe neuropathic pain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Perioperative ketamine for acute postoperative pain
Bell, R. F., Dahl, J. B., Moore, R. A., & Kalso, E. A. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004603.pub2 · Cited by 426
RetractedCentral sensitization: implications for the diagnosis and treatment of pain
Woolf, C. J. (2011) · Pain · doi:10.1016/j.pain.2010.09.030 · Cited by 4,771
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Neuropathic Pain: A Maladaptive Response of the Nervous System to Damage
Costigan, M., Scholz, J., & Woolf, C. J. (2009) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.051508.135531 · Cited by 2,025
Algorithm for neuropathic pain treatment: An evidence based proposal
Finnerup, N. B., Otto, M., McQuay, H. J., Jensen, T. S., & Sindrup, S. H. (2005) · Pain · doi:10.1016/j.pain.2005.08.013 · Cited by 1,330
Dworkin, R. H., O'Connor, A. B., Audette, J., Baron, R., Gourlay, G. K., Haanpää, M. L., Kent, J. L., Krane, E. J., LeBel, A. A., Levy, R. M., et al. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0649 · Cited by 1,325
Ossipov, M. H., Dussor, G. O., & Porreca, F. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43766 · Cited by 1,159
Role of the Immune system in chronic pain
Marchand, F., Perretti, M., & McMahon, S. B. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1700 · Cited by 1,098
Cited by
Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels
Hansen, K. B., Wollmuth, L. P., Bowie, D., Furukawa, H., Menniti, F. S., Sobolevsky, A. I., Swanson, G. T., Swanger, S. A., Greger, I. H., Nakagawa, T., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000131 · Cited by 686
Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy
Peltoniemi, M. A., Hagelberg, N. M., Olkkola, K. T., & Saari, T. I. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0383-6 · Cited by 672
Schwenk, E. S., Viscusi, E. R., Buvanendran, A., Hurley, R. W., Wasan, A. D., Narouze, S., Bhatia, A., Davis, F. N., Hooten, W. M., & Cohen, S. P. (2018) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000806 · Cited by 584
Side-effects associated with ketamine use in depression: a systematic review
Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30272-9 · Cited by 558
Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
Williams, N. R., Heifets, B. D., Blasey, C., Sudheimer, K., Pannu, J., Pankow, H., Hawkins, J., Birnbaum, J., Lyons, D. M., Rodriguez, C. I., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18020138 · Cited by 519
Neuroinflammation and comorbidity of pain and depression
Walker, A. K., Kavelaars, A., Heijnen, C. J., & Dantzer, R. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008144 · Cited by 460
Ketamine – More mechanisms of action than just NMDA blockade
Sleigh, J., Harvey, M., Voss, L., & Denny, B. (2014) · Trends in Anaesthesia and Critical Care · doi:10.1016/j.tacc.2014.03.002 · Cited by 434
Etiology and Pharmacology of Neuropathic Pain
Alles, S. R. A., & Smith, P. A. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014399 · Cited by 395
Ketamine: Current applications in anesthesia, pain, and critical care
Kurdi, M., Theerth, K., & Deva, R. (2014) · Anesthesia: Essays and Researches · doi:10.4103/0259-1162.143110 · Cited by 392
Ketamine: 50 Years of Modulating the Mind
Li, L., & Vlisides, P. E. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00612 · Cited by 385
Psychedelics reopen the social reward learning critical period
Nardou, R., Sawyer, E., Song, Y. J., Wilkinson, M., Padovan-Hernandez, Y., de Deus, J. L., Wright, N., Lama, C., Faltin, S., Goff, L. A., et al. (2023) · Nature · doi:10.1038/s41586-023-06204-3 · Cited by 358
Cohen, S. P., Bhatia, A., Buvanendran, A., Schwenk, E. S., Wasan, A. D., Hurley, R. W., Viscusi, E. R., Narouze, S., Davis, F. N., Ritchie, E. C., et al. (2018) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000808 · Cited by 350
Aleksandrova, L. R., Phillips, A. G., & Wang, Y. T. (2017) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.160175 · Cited by 228
Mechanisms of ketamine and its metabolites as antidepressants
Hess, E. M., Riggs, L. M., Michaelides, M., & Gould, T. D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114892 · Cited by 175
Ketamine applications beyond anesthesia – A literature review
Nowacka, A., & Borczyk, M. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172547 · Cited by 129
Algera, M. H., Kamp, J., van der Schrier, R., van Velzen, M., Niesters, M., Aarts, L., Dahan, A., & Olofsen, E. (2019) · British Journal of Anaesthesia · doi:10.1016/j.bja.2018.12.023 · Cited by 123
Self-citationThreat response system: Parallel brain processes in pain vis-à-vis fear and anxiety
Elman, I., & Borsook, D. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00029 · Cited by 100
Prefrontal cortex miR-29b-3p plays a key role in the antidepressant-like effect of ketamine in rats
Wan, Y.-Q., Feng, J.-G., Li, M., Wang, M.-Z., Liu, L., Liu, X., Duan, X.-X., Zhang, C.-X., & Wang, X.-B. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0164-4 · Cited by 60
Zorumski, C. F., Nagele, P., Mennerick, S., & Conway, C. R. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00172 · Cited by 57
Falk, E., Schlieper, D., van Caster, P., Lutterbeck, M. J., Schwartz, J., Cordes, J., Grau, I., Kienbaum, P., & Neukirchen, M. (2020) · BMC Palliative Care · doi:10.1186/s12904-019-0499-1 · Cited by 57
Siegel, J. S., Palanca, B. J. A., Ances, B. M., Kharasch, E. D., Schweiger, J. A., Yingling, M. D., Snyder, A. Z., Nicol, G. E., Lenze, E. J., & Farber, N. B. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05762-6 · Cited by 50
Addictive potential of novel treatments for refractory depression and anxiety
Kolar, D. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s167538 · Cited by 37
Ketamine: stimulating antidepressant treatment?
Malhi, G. S., Byrow, Y., Cassidy, F., Cipriani, A., Demyttenaere, K., Frye, M. A., Gitlin, M., Kennedy, S. H., Ketter, T. A., Lam, R. W., et al. (2016) · BJPsych Open · doi:10.1192/bjpo.bp.116.002923 · Cited by 29
Chah, N., Jones, M., Milord, S., Al-Eryani, K., & Enciso, R. (2021) · Journal of Dental Anesthesia and Pain Medicine · doi:10.17245/jdapm.2021.21.5.413 · Cited by 19
Pain in an era of armed conflicts: prevention and treatment for warfighters and civilian casualties
George, E., Elman, I., Becerra, L., Berg, S., & Borsook, D. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.04.002 · Cited by 18
Intranasal Ketamine for Abortive Migraine Therapy in Pediatric Patients: A Single-Center Review
Turner, A. L., Shandley, S., Miller, E., Perry, M. S., & Ryals, B. (2020) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2019.10.007 · Cited by 11
Clinical trials for rapid changes in suicidal ideation: lessons from ketamine
Ballard, E. D., Fields, J., Farmer, C. A., & Zarate, C. A. (2021) · Suicide and Life-Threatening Behavior · doi:10.1111/sltb.12663 · Cited by 10
Metadata
- Authors
- Niesters, M., Martini, C., & Dahan, A.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2014-01-22
- Volume
- 77
- Issue
- 2
- Pages
- 357-367
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W1953082779
- Cited by
- 508
- References
- 84
- FWCI
- 13.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.